Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,815 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab.
Kobayashi T, Ito K, Kojima T, Kato M, Kanda S, Hatakeyama S, Matsui Y, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Kamiyama M, Ogawa O, Kitamura H, Nishiyama H; Japan Urological Oncology Group. Kobayashi T, et al. Among authors: miyake m. Cancer Sci. 2021 Feb;112(2):760-773. doi: 10.1111/cas.14762. Epub 2020 Dec 21. Cancer Sci. 2021. PMID: 33283385 Free PMC article.
Role of syndecan-1 (CD138) in cell survival of human urothelial carcinoma.
Shimada K, Nakamura M, De Velasco MA, Tanaka M, Ouji Y, Miyake M, Fujimoto K, Hirao K, Konishi N. Shimada K, et al. Among authors: miyake m. Cancer Sci. 2010 Jan;101(1):155-60. doi: 10.1111/j.1349-7006.2009.01379.x. Epub 2009 Oct 6. Cancer Sci. 2010. PMID: 19860843 Free article.
Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: Long-term follow-up experience at a single institute.
Miyake M, Gotoh D, Shimada K, Tatsumi Y, Nakai Y, Anai S, Torimoto K, Aoki K, Tanaka N, Konishi N, Fujimoto K. Miyake M, et al. Int J Urol. 2015 Jun;22(6):541-7. doi: 10.1111/iju.12749. Epub 2015 Apr 8. Int J Urol. 2015. PMID: 25857336
Changes in oncological outcomes after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma treated in the last two decades: a retrospective analysis based on a multicenter collaborative study.
Miyake M, Tatsumi Y, Fujimoto K, Nagao K, Sakano S, Matsuyama H, Inamoto T, Azuma H, Yasumoto H, Shiina H; Nishinipon Uro-Oncology Collaborative Group. Miyake M, et al. Jpn J Clin Oncol. 2016 Dec;46(12):1148-1155. doi: 10.1093/jjco/hyw128. Epub 2016 Aug 30. Jpn J Clin Oncol. 2016. PMID: 27576438
Diagnostic and prognostic role of urinary collagens in primary human bladder cancer.
Miyake M, Morizawa Y, Hori S, Tatsumi Y, Onishi S, Owari T, Iida K, Onishi K, Gotoh D, Nakai Y, Anai S, Chihara Y, Torimoto K, Aoki K, Tanaka N, Shimada K, Konishi N, Fujimoto K. Miyake M, et al. Cancer Sci. 2017 Nov;108(11):2221-2228. doi: 10.1111/cas.13384. Epub 2017 Sep 15. Cancer Sci. 2017. PMID: 28837258 Free PMC article.
Clinical utility of bioelectrical impedance analysis in patients with locoregional muscle invasive or metastatic urothelial carcinoma: a subanalysis of changes in body composition during neoadjuvant systemic chemotherapy.
Miyake M, Owari T, Iwamoto T, Morizawa Y, Hori S, Marugami N, Shimada K, Iida K, Ohnishi K, Gotoh D, Tatsumi Y, Nakai Y, Inoue T, Anai S, Torimoto K, Aoki K, Yoneda T, Tanaka N, Fujimoto K. Miyake M, et al. Support Care Cancer. 2018 Apr;26(4):1077-1086. doi: 10.1007/s00520-017-3924-0. Epub 2017 Oct 11. Support Care Cancer. 2018. PMID: 29022158
1,815 results